Adstiladrin Goes Global: Ferring Expands Next-Gen Gene Therapy Facility in Finland
To power the global supply chain for growing demand of Adstiladrin, Ferring has taken a bold move in Europe’s advanced therapies industry.
In October 2024, Ferring Pharmaceutical, a global biopharmaceutical company, announced the opening of global manufacturing facility for Adstiladrin, a non-replicating gene therapy, in Finland. This is a significant milestone in Europe’s emergence as a competitive region in biologics manufacturing. This manufacturing hub is spread across 50,000 square feet, and it is designed for the production of Adstiladrin.
To meet the increased demand for Adstiladrin, Ferring has established this facility in Northern Europe, strengthening the region’s capability and scalability of CGT operations. Going forward, as the demand for advanced treatments is accelerating, this facility will support in expanding global supply chain.
Bipin Dalmia, Global Head Uro-Oncology at Ferring Pharmaceuticals, “In January 2024, we announced full commercial availability of Adstiladrin in the U.S. The facility expansion announcement marks an important milestone in ensuring stable and sustainable global supply of Adstiladrin.”
Finland’s Regional Advantage Meets Biotech Innovation
Finland is known for its streamlined regulated framework and skilled workforce, which makes it an emerging hotspot in the Nordic region. This newly opened site is equipped with fully integrated modern technologies, cutting-edge manufacturing suites that help in the development and commercialization of vector-based advanced therapies in large facilities.
Armin Metzger, Executive Vice President & CTO, “Such growth and continue investment and expansion of our gene therapy manufacturing facility, highlights the Ferring’s commitment to provide advanced treatments for patients with bladder cancer”
Europe Paving the Way for Accessible Advanced Therapies
Advanced treatments are currently in high demand as these therapies treat diseases by modifying the gene expression of the living cells. nadofaragene firadenovec-vncg is the only approved intravesical non-replicating gene therapy by the FDA to treat bladder cancer. Furthermore, International Agency for Research on Cancer reported that bladder cancer is the 9th most common cancer across the globe, and the American Cancer Society (ACS) projected that in 2025, about 84,870 individuals will be diagnosed with bladder cancer. Thus, understanding the growing demand of drugs for the treatment of cancer, Ferring’s step marks the access to advanced treatments globally.
“The company is highly focused on maximising its impact and unlocking opportunities to deliver novel solutions to patients”, said Jean-Frédéric Paulsen, Chairman of the Board
